
Abreos Biosciences, a San Diego-based biotech firm, develops assays for personalized dosing and counterfeit detection of therapeutic antibodies.
Abreos Biosciences, founded in San Diego, is an early-stage biotechnology company focused on developing innovative laboratory-based and point-of-care assays. Their core mission is to enhance personalized medicine by enabling precise dosing and counterfeit detection of therapeutic monoclonal antibodies. Abreos Biosciences aims to serve the healthcare market in the United States, providing critical tools for clinicians to optimize treatment outcomes and ensure the authenticity of biologic therapies.
Notable figures affiliated with Abreos Biosciences include experts in biotechnology and healthcare innovation. The company has attracted investment from key players in the biotech sector, bolstering its research and development capabilities. Abreos Biosciences has achieved significant milestones in assay development, contributing to the broader field of personalized medicine. Their impact is evident in improved patient care through tailored therapeutic approaches and enhanced drug safety.

Abpro

Abterra Biosciences
abterrabio.com

AnaBios
anabios.com

Dren Bio
drenbio.com

Abalone Bio
abalonebio.com

OmniAb
omniab.com

AltruBio

RevMAb Biosciences
revmab.com

ABio-X
abio-x.com

Amberstone Biosciences
amberstonebio.com

Avidity Biosciences
aviditybio.com

Abwiz Bio
abwizbio.com

Abacus Bioscience

Adaptive Biotechnologies

Fabrus
fabrus.net
Companies similar to Abreos Biosciences include Abpro, Abterra Biosciences, AnaBios and Dren Bio.
Abreos Biosciences was founded in 2013.
Abreos Biosciences' headquarters is located in San Diego, CA, US.
Abreos Biosciences' most recent funding round was for $5.6M (USD) in September 2020.
As of Sep 15, 2020, Abreos Biosciences has raised a total of $8.6M (USD).
Abreos Biosciences has 6 employees as of Feb 5, 2024.